Published in final edited form as:

J Med Chem. 2012 January 12; 55(1): 528–537. doi:10.1021/jm201436k.

Diarylpropionitrile (DPN) Enantiomers: Synthesis and Evaluation of Estrogen Receptor Beta-Selective Ligands

Vincent M. Carroll^a, M. Jeyakumar^a, Kathryn E. Carlson, and John A. Katzenellenbogen

Department of Chemistry University of Illinois Urbana, IL 61801

Abstract

Two estrogen receptor (ER) subtypes, ER α and ER β , mediate the actions of estrogens in diverse reproductive and non-reproductive target tissues. ER subtype-selective ligands, which bind to and activate these subtypes differentially, have proved to be useful in elucidating which actions of estrogens proceed through ER α vs. ER β . Some of these ligands show potential as novel therapeutic agents. Diarylpropionitrile (DPN), an ER β selective ligand that we developed, is a chiral molecule, but it has been studied almost exclusively as the racemic mixture (*rac*-DPN, **1**). Herein we report the development of an efficient enantioselective synthesis of the two isomers, *R*-DPN (**3**) and *S*-DPN (**2**), and we have compared the *in vitro* ligand binding affinities, coactivator binding affinities and recruitment potencies, and cellular transcriptional potencies of these isomers. Both enantiomers show a very high affinity and potency preference for ER β over ER α , typically in the range of 80–300 fold. Although the enantioselectivity is only modest (3–4 fold), the *R*-enantiomer is the higher affinity and more potent isomer. While ER β can be effectively and selectively stimulated by *rac*-DPN or by either *R*-DPN or *S*-DPN, *R*-DPN might be the preferred member of this isomeric series for biological studies of ER β function.

Introduction

Estrogens function as key regulators of a broad range of physiological processes in various target tissues, and while their actions in the reproductive tract have been well appreciated for a long time, more recent work has highlighted estrogenic responses in many non-reproductive tissues, such as bone, brain and the nervous and cardiovascular systems. An intriguing aspect of the activity of estrogens of different structure is target tissue-selective pharmacology, that is, some estrogens have different levels of intrinsic activity (i.e., agonist character) in different target tissue.^{1, 2} For example, while estradiol stimulates responses in the uterus, breast, bone and liver, the non-steroidal estrogen, raloxifene, blocks estrogen action in the uterus and breast, but has agonistic activity in bone and liver.

It was originally thought that estrogens acted through a single estrogen receptor (ER), and target tissue-selective action was ascribed to the stabilization of different conformations of the ER that were differentially interpreted by the specific constellations of coregulator proteins present in each target tissue and variations in the composition of gene-specific factors, that is, those that operate in connection with the transcriptional modulation of each regulated gene.³ Compounds that showed this target tissue-selective activity were termed

For Correspondence, Contact: John A. Katzenellenbogen Department of Chemistry University of Illinois 600 South Mathews Avenue Urbana, IL 61801 Phone: 217 333 6310 jkatzene@uiuc.edu.

^aContributed equally to this work

Associated Content

Supporting Information. Experimental procedures for the synthesis of **1** and **3**, HPLC traces of **1**, **2** and **3**. This material is free of charge via the Internet at <http://pubs.acs.org>.

selective estrogen receptor modulators (SERMs).^{1, 2} The discovery of a second ER subtype, however, termed ER β (to distinguish it from the original ER, now termed ER α), broadened the modes by which estrogens might be exerting this target tissue-selective pharmacology.⁴⁻⁶ While the precise physiological roles played by the two ER subtypes, ER α and ER β , remain elusive, current evidence, obtained largely from cell-based studies and ER α and ER β knockout mice, suggests—in general—that ER α present in target tissues such as uterus and breast drives proliferation and can contribute to malignant growth in these tissues, whereas ER β is thought to counteract these activities.⁷⁻⁹ Other actions that can be ascribed to ER β relate to regulating malignant growth in the prostate, colon and lung, as well as moderating inflammation and certain aspects of brain behavior, such as depression and aggression.⁷⁻⁹

The discovery of ER β also reinvigorated efforts in ER ligand synthesis, specifically for the development of ER subtype-selective ligands, that is, agonists and antagonists that could selectively regulate the activity of only ER α or only ER β . Such subtype-selective ligands could be used as research tools to decipher the physiological roles of ER α and ER β , but also might be useful leads for the development of novel estrogen therapeutics.^{8, 10} The design of ER β selective ligands has proven to be quite challenging, as a result of the sequence and structural similarity of the ligand binding domains (LBDs) of the two subtypes. Although these receptor subtypes share less than 60% amino acid sequence identity in the LBD, the residues that line the ligand binding pocket are highly conserved; only two out of the 24 amino acids are different (ER α Leu384→ER β Met336, ER α Met421→ER β Ile373). Despite these subtle differences in the receptor binding cavities, there has been significant progress in the development of both steroidal and non-steroidal ER β selective agonists.¹¹

Some time ago, our group described 2,3-bis(*p*-hydroxyphenyl)propionitrile (*rac*-DPN, **1**, **Figure 1**), an ER ligand that exhibits a 170-fold greater relative potency for ER β in transient reporter gene transcription assays.^{12, 13} Many investigators have found DPN to be a useful probe of the unique biology of ER β and a pharmacological alternative to analysis of the phenotype of ER β -knockout animals.¹¹ Despite the presence of a chiral center in DPN and a prediction we made early on that *S*-DPN (**2**) would be the more potent enantiomer,¹⁴ almost all studies with DPN have been done with a racemic mixture of R and S forms (*rac*-DPN, **1**), because this is the form that is readily available. Recently, it has been shown that each DPN enantiomer has different biological effects, and although the absolute stereochemical configuration of each isomer, obtained by chiral HPLC separation, was not determined,¹⁵ the more active enantiomer was designated *S*-DPN, relying on our earlier prediction.¹⁴

We based our prediction that *S*-DPN would be the active enantiomer on our computational modeling of complexes of ER α and ER β with *R*-DPN (**3**) and *S*-DPN, which suggested that there would be a more favorable interaction between Met336 present only in ER β and the nitrile group in *S*-DPN;¹⁴ the importance of this interaction was supported by mutagenesis studies.^{14, 16} To further assess the biological activities of each DPN enantiomer on ER more definitively, however, it is necessary to conduct studies using enantiomerically pure material of carefully defined absolute configuration. Described herein is the first reported asymmetric synthesis of both enantiomers of DPN, relying on an Evans asymmetric alkylation methodology¹⁷ to form the stereocenter, and subsequent functional group interconversions to generate the desired nitrile in a concise fashion and without racemization. With both enantiomers in hand, we compared the *in vitro* ligand binding affinities, coactivator binding affinities and recruitment potencies, and cellular transcriptional potencies of these isomers. Both enantiomers have a very high affinity and potency preference for ER β over ER α , typically in the range of 80-300 fold. Their enantioselectivity is only modest (3-4 fold), and unexpectedly, the R-enantiomer is the higher affinity and more potent isomer. Therefore, *R*-

DPN might be the preferred member of this isomeric series for biological studies of ER β function.

Results

Enantioselective Syntheses of S-DPN and R-DPN

Our synthesis of *S*-DPN (**2**, **Scheme 1**) commenced with the formation of the imide **6** from commercially available 4-methoxyphenylacetic acid (**4**) and (*S*)-(-)-4-benzyl-2-oxazolidinone (**5**).¹⁸ Initial efforts to prepare the desired alkylated product with benzyl chloride as the electrophile gave only minor amounts of **8**; however, upon switching to the benzyl bromide derivative (**7**), the reaction proceeded smoothly in a 79% yield under optimized conditions with NaHMDS as the base.¹⁹ This reaction provided the required lone *S* stereocenter as essentially one diastereomer (**8**) upon recrystallization, as determined by chiral HPLC. Reductive cleavage of the chiral auxiliary, utilizing an *in situ* generated lithium hydroperoxide source, provided the corresponding acid **9** in a 95% yield.²⁰

With the correctly configured *S* stereocenter in hand, elaboration of the acid (**9**) to the nitrile (**2**) was now required, and given the sensitivity of the stereocenter towards epimerization, we considered only mild functional group interconversions. Our initial attempts for effecting this conversion as a one-pot process proved futile, as the conditions gave only poor yields of the intermediate amide and prolonged exposure most likely resulted in epimerization. We then sought a two-step process, involving formation of the amide and subsequent dehydration to the nitrile. It proved difficult to evaluate conditions for these transformations because we were unable to determine the enantiomeric purity of intermediates and products by HPLC unless their methyl ethers were unmasked to give the corresponding diphenols; however, this deprotection step itself introduced additional risk of epimerization. Despite extensive screening of reaction conditions and purifications, the three-step process, involving amidation, dehydration, and deprotection, resulted in significant epimerization, but it was not clear where this epimerization had occurred.

To minimize potential problems with epimerization, we performed each step without silica gel purification, carrying forward only crude material. Surprisingly, conversion of acid **9** to the amide through the appropriate mixed anhydride intermediate suffered from poor yields, and significant amounts of starting material remained. Gratifyingly, under optimized conditions, treatment of acid **9** with isobutyl chloroformate and triethylamine, and subsequent mild aminolysis with ammonia in an isopropyl alcohol solution led cleanly to the amide.²¹ Subsequent dehydration in the presence of trifluoroacetic anhydride and pyridine was rapid and generated the desired nitrile (**2**).²²

The last remaining challenge involved removal of the methyl ether protecting groups because their cleavage often requires relatively forceful conditions that could result in epimerization. While initial attempts to cleave the two methyl ethers were unsatisfactory, the use of 8 equivalents of BBr₃ at low temperatures afforded the desired diphenol (**2**) cleanly, without epimerization, and in high yield and enantiomeric purity (63% over three steps, >99:1 er). To access *R*-DPN, a similar sequence of reactions, now utilizing (*R*)-(+)-oxazolidinone (Supplemental Information) was followed to yield **3** in high enantiopurity (>99:1 er) and yield.

It is of note that the stereochemical assignments we have made for *S*-DPN and *R*-DPN are based on very strong precedents for the diastereoselectivity of the alkylation steps (conversion of compound **6** to **8**),^{23, 24} which in other systems are supported by X-ray crystallographic studies.²⁵ Despite great effort, our attempts to obtain crystals suitable for determining the absolute configurations of the enantiomeric DPNs, **2** and **3**, by direct

crystallographic analysis, however, have not been successful. Nevertheless, we have confidence in our stereochemical assignments.

Measurement of Relative Ligand Binding Affinity (RLA)

The relative ligand binding affinities of the DPN compounds were measured by a competitive radioligand binding assay using [^3H]-17 β -estradiol (E_2) as tracer and full-length human estrogen receptors, ER α and ER β .^{26, 27} The results, summarized in **Table 1**, are expressed as relative ligand binding affinity (RLA) values, and are referenced to the affinity of E_2 set to 100%. Among the three DPNs, the R-enantiomer (**3**) displayed about a 3-fold higher binding affinity for ER β than did the S-enantiomer. The affinity of the racemate (**1**) is essentially the average of that of the two enantiomers, and the RLA value measured for *rac*-DPN in this study is in accord with what we have published earlier for *rac*-DPN.¹² All three DPNs have very low binding affinity for ER α ; consequently, the ratio of RLA values for ER β /ER α are 332, 147 and 305 for R-DPN, S-DPN, and *rac*-DPN, respectively.

Determination of Relative Coactivator-Binding Affinity (RCA) for ER-Ligand Complexes: tr-FRET SRC3 Titration Assay

It is well-known that both ER α and ER β undergo distinct conformational changes upon binding to different estrogens and that these conformational changes result in altered affinity for the coactivator proteins that act as mediators of transcriptional activity.²⁸⁻³⁰ To determine whether the DPNs promote enantiomer-specific conformational changes when bound to each ER subtype, we used our recently described time-resolved fluorescence resonance energy transfer (tr-FRET) assay. With this assay we can quantify the binding affinity of the nuclear receptor interaction domain of steroid receptor coactivator 3 (SRC3-NRID) for ER α or ER β complexed with *rac*-DPN, R-DPN and S-DPN.³¹ Briefly, the ligand binding domain (LBD) of ER α or ER β , labeled with terbium (fluorescence donor), was titrated against increasing concentrations of SRC3 labeled with fluorescein (fluorescence acceptor) in the presence of a saturating concentration of *rac*-DPN, R-DPN and S-DPN or E_2 (reference control). When SRC3 and ER are in close proximity, as would be the case after coactivator recruitment by agonist-bound ER, the energy from the excited state of the terbium complex is transferred to fluorescein, resulting in a FRET signal.^{32, 33} By measuring the degree of FRET we could quantitatively measure the ligand-specific binding of SRC3 to the LBDs of ER α and ER β .

As shown in **Figure 1A** and **1B**, these titrations resulted in a concentration and ligand-specific increase in the magnitude of tr-FRET signal reflecting the binding of SRC3 to different ER α and ER β complexes with the DPNs and E_2 . The control diffusion-enhanced FRET (background) measured in the absence of ER α or ER β LBD (**Figure 1A** and **1B**) was subtracted from the total FRET values, and the resulting specific tr-FRET values are shown in **Figure 1C** and **1D**. Both ER subtypes show full saturation curves with all the ligands, and the concentration of SRC3 at half-maximal binding (EC_{50}) is a measure of the apparent affinity of SRC3 for these differently liganded ER α or ER β complexes. The calculated relative coactivator binding affinity (RCA) values are shown in **Table 2**.

The *rac*-DPN, R-DPN and S-DPN complexes with ER β have a binding affinity for SRC3 that is equivalent to that of the E_2 -ER β complex. However, all three DPN-ER α complexes display RCA values that are about 5-10 times lower than the E_2 -ER α complex (**Figure 1**, **Table 2**). This indicates that with respect to interactions with SRC3, ER α complexes with the DPNs are considerably less potent than the corresponding complexes with ER β ; this difference in coactivator binding affinity likely contributes to the high ER β selectivity of the DPNs. While there was no significant difference in the binding affinity of SRC3 for the three ER β -DPN complexes, some minor differences for DPN-ER α complexes were

observed, with the *R*-DPN-ER α complex having about 2-fold higher affinity for SRC3 than the *S*-DPN-ER α complex; SRC3 bound to the ER α -racemate complex with an RCA approximately the average that of the two enantiomer-ER α complexes. From **Figures 1C** and **1D**, it is evident that the maximal FRET values of SRC3 binding to both ERs complexed with each of the three DPNs are nearly comparable to those of the E₂-bound ERs. This indicates that the DPNs and E₂ form ER complexes that have similar geometry with respect to the FRET donor and acceptor, irrespective of the affinity of SRC3 binding.

Determination of Relative Recruitment Potency (RRP) for Ligand Recruitment of SRC3 for ER α and ER β : tr-FRET Ligand Titration Assay

As an *in vitro* measure of estrogen potency, we used the same tr-FRET assay with the modification in which SRC3 recruitment to the ERs is monitored as a function of increasing ligand concentration. This is a version of the original coactivator recruitment ligand assay (CARLA) described by Wahli.³⁴ For this assay, a 100 nM concentration of Fl-SRC3 was selected, as this gave a near maximum tr-FRET signal and minimum nonspecific signal for the different ligands (**Figure 1C** and **1D**). The background corrected binding curves for the three DPNs and E₂ (**Figure 2A** and **2B**) show that all ligands induced concentration-dependent and receptor-selective binding to both ER subtypes. The ligand concentration that promoted 50% of maximal binding (EC₅₀ in nM), and the respective RRP, an apparent measure of estrogenic potency, are shown in **Table 3**. In agreement with the measured RLAs and RCPs, all three DPNs exhibit higher relative estrogenic potencies in recruiting SRC3 to ER β than to ER α , with β/α ratios of 22-30 fold. In the *in vitro* SRC3 recruitment assay, we reproducibly find that the relative potency of *R*-DPN is higher with both ER subtypes, about 3-fold with ER β and about 2-fold with ER α compared to *S*-DPN, while that of *rac*-DPN is the average of the potency of the two enantiomers.

Measurement of the Relative Cellular Potencies (RCP) of DPNs: Transient Transfection Assay

To examine how the *in vitro* ER subtype-specific ligand binding and SRC3 recruitment activities of the DPNs relate to a cellular response, we tested the transcriptional effects of the three DPNs in transient transfection reporter gene assays. For this, we first used human endometrial cancer cells (HEC-1) wherein we have previously reported that the *rac*-DPN displayed transactivation selectivity (β/α) of about 170-fold.¹² In these cells, following transient transfection of an ERE-driven Luciferase and full-length human ER α or ER β expression plasmids, the transcriptional response (Luciferase activity) was measured as a function of doses of the three DPNs or E₂. The results, shown in the **Figure 3** left panel top (ER α) and bottom (ER β) and **Table 4**, indicate that while *rac*-DPN, *R*-DPN and *S*-DPN are ER β selective, there was no difference in the potency with which the three DPNs activated ER β or ER α . The measured RCPs for *rac*-DPN, *R*-DPN and *S*-DPN were 0.040, 0.039 and 0.04% for ER α and 6.3, 6.7 and 6.1% for ER β , respectively. In this reporter gene assay, *rac*-DPN retained ER β subtype selectivity equivalent to that we reported earlier (β/α ratio of 153 vs. 170 (**Figure 3** and **Table 4**)).¹²

In our earlier study, we reported that some ER agonists recruit SRC3 at greater levels, both in RCAs and RRP, than that would be predicted from their RLAs and that these ligands were found to have higher transcriptional potencies in cells upon cotransfection with SRC3.³¹ Therefore, it was thought that the 3-fold higher RRP measurement seen for *R*-DPN vs. *S*-DPN in the *in vitro* assay would be reflected in reporter gene assays if cellular SRC3 protein levels were elevated. As in our previous study,³¹ we chose the U2OS cell line that has been shown to express low level of endogenous SRC3, and we performed reporter gene assays with and without cotransfected SRC3. The results indicate that even under these conditions, all three DPNs (**Figure 3**, **Table 4**) have similar cellular RCPs as observed in the

HEC-1 cells for ER α (**Figure 3** right panel top) and ER β (**Figure 3** right panel bottom). The transcriptional selectivity of *rac*-DPN for ER β in U2OS cells is comparable to the values obtained in HEC1 cells, with β/α ratios of 150 and 153, respectively. Comparable potency measurements and ER β selective activities were observed for all three DPNs in U2OS cells in the absence of transfected SRC3 (data not shown).

DISCUSSION

The discovery of the second estrogen receptor, ER β , expanded the pathways by which the diverse effects of estrogens might be functioning, and it offered the tantalizing possibility of obtaining new activities or achieving higher levels of selectivity by the development of ER subtype-selective ligands.^{8, 10} Such subtype-selective estrogens might support bone and cardiovascular health and suppress hot flush in menopausal women without placing them at increased risk of breast and uterine cancers; other agents might be useful in treating benign prostatic hypertrophy or prostate cancer.^{8, 10} Studies that mapped the different distributions of ER α and ER β in different target tissues, and the phenotypes of mice in which ER α or ER β were selectively knocked out added further intrigue.³⁵ Not surprisingly, significant efforts were made in the development of ligands that would selectively discriminate between the two ERs, ER α and ER β , in terms of potency or agonist or antagonist intrinsic activity; much of this work has been recently summarized,¹¹ and some of these new compounds are the subject of continuing investigations.

Diarylpropionitrile (DPN) Ligands: ER Subtype Selectivity and Enantioselectivity

Early on, our laboratory developed a number of ER subtype-selective ligands that have been widely used in studies mapping the underlying estrogen biology mediated by ER α and ER β ; the most notable of these are a propyl pyrazole triol (PPT),³⁶ which is highly specific for ER α , and DPN, a ligand with high preferential affinity and potency for ER β .¹² DPN is a chiral molecule, and most studies to date have used it as the racemate, due to its commercial availability in this form. In the present study, we have developed an enantioselective route for the synthesis of both enantiomers of DPN, *R*-DPN and *S*-DPN, and we have compared them, as well as the racemate, *rac*-DPN, in terms of their binding affinity to both ER α and ER β , the affinity that their complexes with the ERs confer for a coactivator (SRC3), and the potency with which they recruit SRC3 to ERs *in vitro*, as well for their cellular potency in stimulating transcription of an ERE-driven reporter through ER α and ER β in two cell lines. In all of these assays, we considered both the *ER subtype selectivity* of the three DPNs as well as their *enantioselectivity*.

Competitive ligand binding experiments with full-length human ER α and ER β proteins indicate that all three DPNs are ER β -selective, with binding affinities for ER β being much higher than ER α . (The β/α RLA ratio we report here for *rac*-DPN is somewhat greater than that which we reported in our prior publication. Any small variation in the very low RLA values for ER α become greatly exaggerated in the β/α ratio, so it is not surprising to see some variation in this number (170/305); however, the higher, therefore more accurate, ER β RLA remains the same as before.¹²) In terms of enantioselectivity, the *R*-isomer has about 3-fold higher RLA for ER β than does the *S*-enantiomer, with that of *rac*-DPN being the average of the two enantiomers. Similarly, our results from the *in vitro* tr-FRET coactivator titration assay (RCA) indicate that *rac*-DPN, *R*-DPN or *S*-DPN form complexes with ER β that have very high affinity for SRC3, comparable to that of E₂; by contrast, the ER α complexes with the DPNs have 6-13 lower affinity for SRC3 than the ER β complexes, suggesting that SRC binding affinity might also be contributing to their ER β potency selectivity. There is, again, limited enantioselectivity in this assay, and this is present only with ER α . In the assays of the *in vitro* potency of DPNs by the tr-FRET ligand titration

assays (RRP), the three DPNs again show pronounced subtype selectivity in recruiting SRC3 to ER β than to ER α , with β/α ratio of 22-30. Their enantioselectivity in this assay is also limited, with the potency of *R*-DPN with ER β being about 3-fold higher than *S*-DPN.

In transient transfection assays using HEC-1 cells, all three DPNs were ER β potency selective, with β/α ratios of 147-172. This is consistent with the *in vitro* RLA, RCA and RRP measurements described above, as well as with our earlier results with *rac*-DPN assayed in HEC-1 cells.¹² In this transfection assay, however, the three DPNs showed essentially no enantioselectivity, all having comparable potencies in activating ER β -mediated transcriptional responses. Recently, we reported that some ER agonists recruit SRC3 at greater levels than that would be predicted from their RLAs and that these ligands were found to have higher transcriptional potencies in cells upon cotransfection with SRC3.¹² We examined this in U2OS cells because these cells have a very low level of endogenous SRC3; thus, cotransfection with an expression plasmid for human full-length SRC3 results in a 5-6 fold increase in SRC3 protein levels.³¹ Even under these conditions, however, the potency with which *rac*-DPN, *R*-DPN and *S*-DPN activated the ERE-luciferase activity via ER β was essentially unchanged, and no enantioselectivity became evident. It is likely that the limited enantioselectivity shown by the DPN enantiomers, which is only a 3-4 fold, can be readily measured in the *in vitro* assays, which are constituted of purified components, but is too small to have a significant effect in the cell-based reporter gene assay, which operates in a much more complex context.

Degree of DPN Enantioselectivity

Although DPN is a chiral molecule and ligand-receptor interactions typically show pronounced enantioselective behavior, the difference between *R*-DPN and *S*-DPN in terms of the affinity and potency measures we have studied here is only limited, typically in the range of 3-4 fold, with the *R*-enantiomer being the higher affinity and more potent analog. Gratifyingly, when enantioselectivity is observed, the racemate, *rac*-DPN, has an affinity or potency that is very close to the average that of both enantiomers. Also, the two enantiomerically pure DPNs show the same high affinity and potency preference for ER β as did the racemate, with β/α ratios being in the range of 70-300, depending on the assay. Thus, the DPNs have an ER β subtype selectivity that is in the range of the very best of the ER β -selective ligands thus far reported.¹¹ Even though the ER β ligand binding pocket is relatively small, smaller than that of ER α ,³⁷ the limited enantioselectivity of DPN is perhaps not surprising: Because the molecule is relatively flexible, the two enantiomers can adopt conformations that are nearly superimposable and therefore are apparently not distinguishable by the ERs to any great extent. By contrast, another ER β -selective ligand, which has a more rigid tetracyclic structure, shows very high enantioselectivity.³⁸

Assignment of DPN Absolute Configuration

When we first prepared DPN, it was a racemate, and though we, and many others, studied it as a racemate, early on we predicted that *S*-DPN would be the more potent enantiomer.¹⁴ This prediction was based on our computational modeling of complexes of ER α and ER β with *R*-DPN and *S*-DPN in which we observed what appeared to be a more favorable interaction between Met336 present only in ER β and the nitrile group in *S*-DPN.¹⁴ The importance of this interaction appeared to be supported by concurrent mutagenesis studies;^{14, 16} however, the assignment remained a speculation, because we had no way to make a definitive assignment of absolute stereochemistry. The stereochemical course of the Evans asymmetric alkylation of chiral oxazolidinones,^{17, 24} however, has enabled us to make a more definitive assignment of the DPN enantiomers, and we were able to determine that it was the *R*-enantiomer of DPN that showed somewhat, but consistently, higher affinity and greater potency. Thus, it appears that our original speculation concerning absolute

configuration was incorrect,¹⁴ which is another reminder of the inherent uncertainties of computation modeling of ligand-receptor interactions.

The receptor binding affinity measurements (RLAs) and cellular potencies (RCPs) for the DPNs that we prepared by our enantioselective syntheses differ in a number of respects from those reported in 2009 by Weiser et al. for samples of *R*-DPN and *S*-DPN that were obtained by chiral HPLC separation.¹⁵ These investigators reported that one enantiomer bound to ER β with a 6.7-fold higher affinity than the other, with measured K_i values of 0.27 and 1.82 nM, respectively. They also found significant differences in their binding affinities to ER α . In reporter gene assays, only one enantiomer stimulated an ERE-regulated luciferase reporter gene via ER β , while they found that the other was selectively active through ER α .¹⁵ It appears that these investigators did not make an experimental determination of the absolute configuration of their chromatographically separated DPN enantiomers, but designated their higher affinity, more potent enantiomer as *S*, referring to our earlier modeling paper in which we suggested that *S*-DPN was the more potent isomer.¹⁴ Considering our current reversal of preferred configuration, their more potent enantiomer is likely also *R*-DPN.

Irrespective of the likely reversal of preferred configuration, there are a number of differences between how assays were performed in our study and in the 2009 study by Weiser et al.¹⁵ that might underlie the quantitative differences between our results. For binding studies, we used human ER β protein obtained from a baculovirus-insect cell expression system (from Pan Vera, Madison, WI), whereas rat ER β protein made in reticulocyte lysate via an *in vitro* coupled transcription-translation system was used in the other study. Furthermore, human and rat ER β were used in the respective transient transfection assays. Rat ER β was used for binding and cell-based assays in the Weiser et al. study because their work on the DPN enantiomers also included behavioral assays in rats. There are, however, quite a number of amino acid sequence differences between the ligand binding domains of rat ER β and human ER β (8 conservative and 11 non-conservative changes), and these changes might account for some of the differences observed between the two studies. The cell lines used for the reporter gene assays were also different: A mouse hypothalamic cell line, N-38, was used in the Weiser et al. study, whereas we used human endometrial HEC-1 cells and osteosarcoma-derived U2OS cells.¹⁵ It is of note that N-38 cells appear to have high basal activity for both ER subtypes (ER β 300% and ER α 185% of empty vector control), so that only a limited dose response to the DPNs and E2 was observed.

Conclusion

We have developed an efficient enantioselective synthesis of *R*-DPN and *S*-DPN that has enabled these two stereoisomers to be compared in terms of their binding affinity and potency in several *in vitro* and cell-based assays for the estrogen receptor. Both enantiomers retain the very high affinity and potency preference of *rac*-DPN for ER β over ER α , which is in the range of 80-300 fold. While in our hands the enantioselectivity is only modest (3-4 fold), the *R*-enantiomer is the higher affinity and more potent isomer. Thus, *R*-DPN might be the preferred member of this isomeric series for biological studies on ER β function. This conclusion is presented in only a tentative manner because it is becoming evident that various ER β ligands that are nominally similar in their patterns of receptor binding affinity and potencies in simple cell-based assays, can demonstrate considerably different patterns of activity in more complex *in vivo* contexts, as we recently demonstrated in a study where *rac*-DPN was compared to other ER β -selective ligands, chloroindazoles and ERB-041.³⁹ While nominally similar in ER β binding affinity, selectivity and reporter gene activation, these three ligands had very different ER β -dependent cell regulatory activities. Thus, it is not clear

that *rac*-DPN, *R*-DPN and *S*-DPN will be as equivalent in the regulation of various cell activities as one might expect based on the relatively limited enantioselectivity in their binding and reporter gene activities.

Experimental Section

General

All reactions were carried out under a nitrogen atmosphere with dry solvents using anhydrous conditions unless otherwise stated. THF, DCM and PhCH₃ used in the reactions were dried in a solvent delivery system (neutral alumina column). Reagents were purchased from Aldrich and used without further purification, unless otherwise stated. Yields refer to chromatographically and spectroscopically (¹H NMR) homogeneous materials, unless otherwise stated. Reactions were monitored by thin layer chromatography (TLC) carried out E. Merck silica gel 60 F254 precoated plates (0.25 mm) using UV light as the visualizing agent and ceric ammonium molybdate and heat as developing agents. Flash column chromatography was performed on Silica P Flash silica gel (40-64 μM, 60 Å) from SiliCycle. ¹H NMR spectra were recorded at 23 °C on a Varian Unity-400, Varian Inova-500 or Varian Unity-500 spectrometers and are reported in ppm using residual protium as the internal standard (CHCl₃, δ = 7.26, CD₂H₂N, δ = 1.94, center line, acetone-*d*₆, δ = 2.05, center line). The following abbreviations were used to explain the multiplicities: s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m = multiplet and b = broad. Proton-decoupled ¹³C NMR spectra were recorded on a Varian Unity-500 (126 MHz) spectrometer and are reported in ppm using solvent as an internal standard (CDCl₃, δ = 77.16, CD₃CN, δ = 1.30, center line, acetone-*d*₆, δ = 29.80, center line). High resolution mass spectra were obtained at the University of Illinois Mass Spectrometry Laboratory. The purities of target compounds were 95%, measured by HPLC using a Waters 1525 binary HPLC pump equipped with a Waters in-line degasser AF, Waters 2487 Dual λ absorbance detector and a Symmetry C18 5 μm 4.6 × 150 mm column (Part No. WAT045905). Chiral high pressure liquid chromatographic (HPLC) analysis was performed using a Waters 1525 binary HPLC pump equipped with a Waters in-line degasser AF, Waters 2487 Dual λ absorbance detector and a Regis Technologies (R,R)-Whelk-O® 2 column (Particle Size: 10 μm, 100 Å, Column Dimensions: 25 cm × 4.6 mm, Cat. #: 786315). Optical rotations were obtained using a JAS.CO DIP-370 Digital Polarimeter and a 3.5 × 50 mm cell and are reported as follows: concentration (c = g / 100 mL), solvent. Melting points were recorded on a Thomas Hoover Uni-Melt 6427-F10 Capillary Melting-Point Apparatus. [³H]-17β-Estradiol, specific activity 89 Ci/mmol (3293 GBq/mmol) was purchased from Perkin Elmer Life Science (Boston, MA). 17β-Estradiol (17β-E₂) was obtained from Sigma (St. Louis, MO). Purified full-length human ERα and ERβ were purchased from Pan Vera (Madison, WI). The thiol reactive fluorophore, 5-iodoacetamido fluorescein and terbium labeled streptavidin were obtained from Molecular Probes/Invitrogen (Eugene, CA). Thiol reactive biotin derivative (MAL-dPEG4-biotin) was from Quanta BioDesign (Powell, OH).

(S)-4-Benzyl-3-(2-(4-methoxyphenyl)acetyl)oxazolidin-2-one (6)

To a mixture of 4-methoxyphenylacetic acid (**4**, 2.80 g, 16.9 mmol) and (*S*)-4-benzyl-2-oxazolidinone (**5**, 1.50 g, 8.46 mmol) in PhCH₃ (15 mL) at room temperature was added triethylamine (4.72 mL, 33.9 mmol).¹⁸ The clear solution was heated to 80 °C for 10 min and then a solution of pivaloyl chloride (2.08 mL, 16.9 mmol) in PhCH₃ (3.5 mL) was added dropwise. After full addition, the reaction mixture was refluxed for 14 h before being cooled to room temperature and quenched with 1 M HCl (20 mL), extracted with EtOAc (2 × 50 mL), and the combined organic extracts were washed with 5% NaHCO₃ solution (15 mL), dried over MgSO₄ and concentrated *in vacuo*. Purification by column chromatography

(Hex:EtOAc, 2:1, to Hex:EtOAc:MeOH, 1:1:0.1) and recrystallization (PhCH₃:Hex, 1:1) afforded **6** (2.07 g, 75.2%) as a white solid; mp 80-82 °C. *R*_f = 0.31 (Hex:EtOAc, 2:1). ¹H NMR (500 MHz, CDCl₃) δ 7.31-7.22 (m, 5H), 7.13 (d, *J* = 6.6 Hz, 2H), 6.88 (d, *J* = 8.8 Hz, 2H), 4.69-4.61 (m, 1H), 4.30-4.13 (m, 4H), 3.79 (s, 3H), 3.25 (dd, *J* = 13.3, 3.2 Hz, 1H), 2.74 (dd, *J* = 13.4, 9.5 Hz, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 171.6, 158.8, 153.4, 130.8, 129.4, 128.9, 127.3, 125.4, 114.0, 66.1, 55.3, 55.2, 40.7, 37.7. HRMS (ESI) calc'd for C₁₉H₂₀NO₄ [*M* + 1] 326.1392; found 326.1392.

(S)-4-Benzyl-3-((S)-2,3-bis(4-methoxyphenyl)propanoyl)oxazolidin-2-one (**8**)

To a solution of **6** (0.10 g, 0.31 mmol) in THF (1 mL) at -78 °C was added NaHMDS (1.0 M in THF, 0.33 mL, 0.33 mmol) dropwise and left to stir at this temperature for 1 h.¹⁹ 4-Methoxybenzyl bromide (**7**, 90 μL, 0.61 mmol) was then added at -78 °C dropwise and left to stir to room temperature over 5 h before being quenched with H₂O (10 mL). The crude reaction was extracted with EtOAc (2 × 20 mL), and the combined organic extracts were dried over MgSO₄ and concentrated *in vacuo*. Purification by column chromatography (Hex:EtOAc, 3:1) and recrystallization (Hex:EtOAc, 1:1) afforded **8** (0.11 g, 79.4%, dr >99:1) as a white solid; mp 169-171 °C. *R*_f = 0.54 (Hex:EtOAc, 2:1). [*α*]_D²³ 145.9 (*c* 1.2, CHCl₃). ¹H NMR (500 MHz, CDCl₃) δ 7.36 (d, *J* = 8.8 Hz, 2H), 7.29-7.22 (m, 5H), 7.17 (d, *J* = 8.4 Hz, 2H), 6.85 (d, *J* = 8.8 Hz, 2H), 6.80 (d, *J* = 8.6 Hz, 2H), 5.38 (dd, *J* = 9.5, 5.7 Hz, 1H), 4.60-4.53 (m, 1H), 4.04-3.99 (m, 2H), 3.79 (s, 3H), 3.75 (s, 3H), 3.44 (dd, *J* = 13.1, 9.4 Hz, 1H), 3.04-2.92 (m, 2H), 2.59 (dd, *J* = 13.5, 8.8 Hz, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 173.7, 158.9, 158.1, 152.8, 135.0, 131.1, 130.3, 130.3, 129.7, 129.4, 128.8, 127.2, 114.0, 113.7, 65.5, 55.3, 55.2, 55.2, 49.6, 39.7, 37.5. HRMS (ESI) calc'd for C₂₇H₂₈NO₅ [*M* + 1] 446.1967; found 446.1970.

(S)-2,3-bis(4-methoxyphenyl)propanoic acid (**9**)

To a solution of **8** (1.01 g, 2.27 mmol) in THF:H₂O (120 mL, 5:1) at 0 °C was added H₂O₂ (30% wt in H₂O, 14.3 mL) and LiOH (54.3 mg, 2.27 mmol). The resulting white suspension was stirred at 0 °C for 3 h before being quenched with cold 0.1 M HCl (20 mL).²⁰ The residue was extracted with EtOAc (2 × 100 mL), and the combined organic extracts were dried over MgSO₄ and concentrated *in vacuo*. Purification by column chromatography (EtOAc:Hex, 2:1) afforded **9** (0.63 g, 96.6%) as an off-white solid; mp 117-119 °C. *R*_f = 0.21 (Hex:EtOAc, 2:1). [*α*]_D²³ -138.61 (*c* 1.0, CHCl₃). ¹H NMR (500 MHz, CDCl₃) δ 7.21 (d, *J* = 8.8 Hz, 2H), 7.01 (d, *J* = 8.4 Hz, 2H), 6.84 (d, *J* = 8.8 Hz, 2H), 6.77 (d, *J* = 8.6 Hz, 2H), 3.82-3.71 (m, 7H), 3.31 (dd, *J* = 13.9, 8.4 Hz, 1H), 2.95 (dd, *J* = 13.8, 7.2 Hz, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 179.4, 159.0, 158.1, 130.8, 130.0, 129.9, 129.1, 114.0, 113.7, 55.2, 55.2, 52.8, 38.4. HRMS (ESI) calc'd for C₁₇H₁₈O₄Na [*M* + 1] 309.1103; found 309.1103.

(S)-2,3-Bis(4-hydroxyphenyl)propanenitrile (**2**)

To a solution of **9** (50.1 mg, 0.18 mmol) in triethylamine (36.6 μL, 0.26 mmol) and THF (4 mL) at -20 °C was added isobutyl chloroformate (45.5 μL, 0.35 mmol). The resulting solution was stirred for 20 min at -20 °C, followed by the addition of ammonia (2.0 M in IPA, 0.88 mL, 1.75 mmol) and left to stir for an additional 20 min at -20 °C before being quenched by passing through a Celite plug. The crude solution was concentrated *in vacuo*, redissolved in THF (1.5 mL) and cooled to 0 °C, followed by addition of pyridine (60.9 μL, 0.75 mmol) and trifluoroacetic anhydride (51.1 μL, 0.37 mmol). The mixture was left to stir at 0 °C for 5 min before being quenched passing through a Celite plug and evaporation of solvent. The crude was redissolved in DCM (1.5 mL), cooled to -78 °C and BBr₃ (1.0 M in DCM, 1.5 mL, 1.50 mmol) was added dropwise over 5 min. The resulting mixture was left to warm to room temperature over 3 h before being quenched upon slow addition of MeOH

at 0 °C. The crude solution was passed through a Celite plug, concentrated *in vacuo* and recrystallized (Hex:EtOAc, 1:1) to afford **2** (26.5 mg, 63.2% over 3 steps) as an off-white solid; mp 190-192 °C. $[\alpha]_D^{23}$ 1.386 (*c* 1.1, MeOH). R_f = 0.73 (Hex:EtOAc, 1:2). ^1H NMR (500 MHz, acetone- d_6) δ 7.19 (d, J = 8.6 Hz, 2H), 7.06 (d, J = 8.4 Hz, 2H), 6.83 (d, J = 8.6 Hz, 2H), 6.75 (d, J = 8.1 Hz, 2H), 4.16 (t, J = 7.6 Hz, 1H), 3.11-3.00 (m, 2H). ^{13}C NMR (126 MHz, CD_3CN) δ 157.7, 157.0, 131.4, 129.9, 129.4, 128.2, 122.2, 116.6, 116.1, 41.4, 39.4. HRMS (ESI) calc'd for $\text{C}_{15}\text{H}_{13}\text{NO}_2\text{Na}$ 262.0844; found 262.0846.

Protein Expression, Purification, and Labeling of ER α -417, ER β -369, and SRC3—The pET15b bacterial expression plasmids encoding six-His fusion proteins of human ER LBDs, ER α -417 (amino acids 304-554) and ER β -369 (amino acids 256-505), each with a single reactive cysteine at C417 or C369, respectively, and the nuclear receptor interaction domain (NRID) of human steroid receptor coactivator 3 (SRC3) encompassing 3 NR boxes (amino acids 627-829) have been described previously, as have the methods for protein expression and purification.^{32, 40} ER LBDs and the SRC3 fragment were respectively labeled with MAL-dPEG4-biotin and 5-iodoacetamido fluorescein, according to the previously published procedure.⁴⁰

Radiometric Competitive Binding Assay to Determine Relative Ligand-Binding Affinity (RLA)—RLAs (previously referred to as Relative Binding Affinities; RBAs) were determined by competitive radiometric binding assays using 0.5 nM full length human ER α or ER β in the presence of 2 nM [^3H]-17 β -E $_2$, and various concentrations of unlabeled 17 β -E $_2$, *rac*-DPN, *R*-DPN and *S*-DPN as previously described.^{26, 27} The concentrations of unlabeled 17 β -E $_2$ and different DPNs required to reduce the binding of [^3H]-17 β -E $_2$ by 50% (IC_{50}) were obtained from the displacement curves. The RLA values of *rac*-DPN, *R*-DPN, and *S*-DPN were determined using the following equation:

$$RLA(DPN) = \{IC_{50}(17\beta-E_2) / IC_{50}(DPN)\} \times 100$$

SRC3 Titration Assay: Determination of Relative Coactivator-Binding Affinity (RCA)—These assays were performed as recently described.³¹ Different concentrations of fluorescein-labeled SRC3 fragment (FI-SRC3) were prepared in buffer A (50 mM Tris pH 7.9, containing 10% glycerol, 0.01% Nonidet P-40, 50 mM KCl, 2 mM β -mercaptoethanol, 2% dimethylformamide and 0.3 mg/mL ovalbumin). Streptavidin-terbium (SA-Tb) and biotinylated-ER α or ER β LBD were premixed in buffer A. Ligand dilutions were made in buffer B (20 mM Tris pH 7.9, and 100 mM NaCl containing 2% dimethylformamide) to improve solubility. Aliquots of SA-Tb-ER α or SA-Tb-ER β cocktail and FI-SRC3 were added to the wells of a 96-well black microplate (Molecular Devices, Sunnyvale, CA), followed by the addition of the ligands. The final assay concentrations were 0.25 nM SA-Tb, 1 nM ER α LBD or 1 nM ER β LBD, 25 μM E $_2$, *rac*-DPN, *R*-DPN and *S*-DPN and indicated concentrations of FI-SRC3. Non-specific binding was determined by parallel incubations that contained all the components, but without biotinylated ER LBD, and was used to correct for diffusion-enhanced FRET. After 1 h incubation at room temperature in the dark, the plates were measured for tr-FRET. The background diffusion enhanced FRET values (control) were subtracted from the corresponding test samples (total FRET) and the resulting specific FRET values were plotted against the log FI-SRC3 concentrations. The concentration of SRC3 that gave 50% (EC_{50}) of maximal binding in the presence of 17 β -E $_2$ and different DPN preparations were obtained from the respective binding curves for both ER α and ER β LBDs. Data were analyzed by nonlinear regression with an equation for the sigmoidal dose response (variable slope) in Prism 5 GraphPad (San Diego, CA). The relative

coactivator-binding affinity (RCA) values of SRC3 for ER α or ER β complexed with different ligands were determined as previously described.³¹

Ligand Titration Assay: Determination of Relative Recruitment Potency (RRP)

—These assays were performed as recently described.³¹ The following reaction components were individually made: a premixture of SA-Tb and ER α or ER β , Fl-SRC3 and ligand dilutions. An aliquot of SA-Tb-LBD premixture, and Fl-SRC3 were added first to the plate and then followed by the addition of the serially diluted ligands and incubated for 1 h before measuring tr-FRET. Control wells had all the components except biotinylated ER LBD. The final reaction concentrations were 0.25 nM SA-Tb, 1 nM ER α , LBD or 1 nM ER β LBD, 100 nM Fl-SRC3 and indicated ligand concentrations. The concentrations of E₂ and DPNs required to give 50% (EC₅₀) of SRC3 recruitment were obtained from each of the binding curves from both ER α and ER β LBDs, and the relative recruitment potency (RRP) values for other ligands were calculated as previously reported.³¹

tr-FRET Measurements—tr-FRET was measured on a Wallac Victor II plate reader (Perkin Elmer Life Sciences, Waltham, MA). The donor, SA-Tb, was excited at 340/80 nm. Emissions from the donor (D) and the acceptor fluorescein (A) were monitored at 495/20 and 520/25 nm respectively with a 100 μ s delay. Tr-FRET is expressed as $A/D \times 1000$.³³

Transcriptional Activation Assay—Human endometrial cancer-1 (HEC-1) cells, or U2OS, a human osteosarcoma derived cell line were grown in MEM containing phenol red, 5% calf serum and 100 μ g/ml penicillin/streptomycin. Cells were then cultured at least six days in phenol red-free MEM supplemented with 5% charcoal-dextran stripped calf serum, seeded into 24-well plates (5×10^4 cells/well) and transfected with 0.5 μ g ERE-Luciferase, 0.05 μ g full-length hER α or hER β and the internal control pCMV- β -gal (0.05 μ g).⁴¹ In transfection assays with U2OS cells, cells were co-transfected with 0.3 μ g pCMX-hSRC3 or pCMX empty vector (for experiments that did not require SRC3 expression) in addition to the expression plasmids used for HEC-1 cells.³¹ At 6 h post-transfection, cells were treated with increasing concentrations of *rac*-DPN, *R*-DPN and *S*-DPN or 17 β -E₂, and 24 h later cells were harvested and assayed for luciferase and β -galactosidase activities.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We are grateful for support of this research from a grant from the National Institutes of Health (PHSR37 DK015556). We thank Megan Treutle Phillips for early efforts on this project.

Abbreviations

A	FRET acceptor
D	FRET donor
DPN	diarylpropionitrile
E ₂	estradiol
ER	estrogen receptors
Fl	fluorescein
LBD	ligand binding domain

NRID	nuclear receptor interaction domain
RCA	relative coactivator binding affinity
RLA	relative ligand binding affinity
RCP	relative cellular potencies
RRP	relative recruitment potency
SRC3	steroid receptor coactivator 3
Tb	terbium
tr-FRET	time-resolved fluorescence resonance energy transfer

References

1. McDonnell DP. The Molecular Pharmacology of SERMs. *Trends Endocrinol Metab.* 1999; 10:301–311. [PubMed: 10481160]
2. McDonnell DP. Selective estrogen receptor modulators (SERMs): A first step in the development of perfect hormone replacement therapy regimen. *J Soc Gynecol Investig.* 2000; 7:S10–S15.
3. Smith CL, O'Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. *Endocr Rev.* 2004; 25:45–71. [PubMed: 14769827]
4. Kuiper GG, Enmark E, Peltö-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. *Proc Natl Acad Sci U S A.* 1996; 93:5925–5930. [PubMed: 8650195]
5. Kuiper GG, Gustafsson JA. The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. *FEBS Lett.* 1997; 410:87–90. [PubMed: 9247129]
6. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. *FEBS Lett.* 1996; 392:49–53. [PubMed: 8769313]
7. Lindberg MK, Moverare S, Skrtic S, Gao H, Dahlman-Wright K, Gustafsson JA, Ohlsson C. Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, supporting a “ying yang” relationship between ERalpha and ERbeta in mice. *Mol Endocrinol.* 2003; 17:203–208. [PubMed: 12554748]
8. Nilsson S, Gustafsson JA. Estrogen receptors: therapies targeted to receptor subtypes. *Clin Pharmacol Ther.* 2011; 89:44–55. [PubMed: 21124311]
9. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen receptor beta: an overview and update. *Nucl Recept Signal.* 2008; 6:e003. [PubMed: 18301783]
10. Harris HA. Estrogen receptor-beta: recent lessons from in vivo studies. *Mol Endocrinol.* 2007; 21:1–13. [PubMed: 16556737]
11. Minutolo F, Macchia M, Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor beta ligands: Recent advances and biomedical applications. *Med Res Rev.* 2011; 31:364–442. [PubMed: 19967775]
12. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. *J Med Chem.* 2001; 44:4230–4251. [PubMed: 11708925]
13. Sun J, Meyers MJ, Fink BE, Rajendran R, Katzenellenbogen JA, Katzenellenbogen BS. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. *Endocrinology.* 1999; 140:800–804. [PubMed: 9927308]
14. Sun J, Baudry J, Katzenellenbogen JA, Katzenellenbogen BS. Molecular basis for the subtype discrimination of the estrogen receptor-beta-selective ligand, diarylpropionitrile. *Mol Endocrinol.* 2003; 17:247–258. [PubMed: 12554752]

15. Weiser MJ, Wu TJ, Handa RJ. Estrogen receptor-beta agonist diarylpropionitrile: biological activities of R- and S-enantiomers on behavior and hormonal response to stress. *Endocrinology*. 2009; 150:1817–1825. [PubMed: 19074580]
16. Shiau AK, Barstad D, Radek JT, Meyers MJ, Nettles KW, Katzenellenbogen BS, Katzenellenbogen JA, Agard DA, Greene GL. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. *Nat Struct Biol*. 2002; 9:359–364. [PubMed: 11953755]
17. Evans DA. Studies in asymmetric synthesis. The development of practical chiral enolate synthons. *Aldrichimica Acta*. 1982; 15:23–32.
18. Prashad M, Kim H-Y, Har D, Repic O, Blacklock TJ. A convenient and practical method for N-acylation of 2-oxazolidinone chiral auxiliaries with acids. *Tetrahedron Lett*. 1998; 39:9369–9372.
19. Heemstra JM, Kerrigan SA, Doerge DR, Helferich WG, Boulanger WA. Total Synthesis of (S)-Equol. *Org. Lett*. 2006; 8:5441–5443. [PubMed: 17107042]
20. Stang EM, Christina WM. Total synthesis and study of 6-deoxyerythronolide B by late-stage C-H oxidation. *Nat. Chem*. 2009; 1:547–551. [PubMed: 21378935]
21. Taylor JG, Li X, Oberthuer M, Zhu W, Kahne DE. The Total Synthesis of Moenomycin A. *J. Am. Chem. Soc*. 2006; 128:15084–15085. [PubMed: 17117848]
22. Barbosa, AJM.; Brunette, SR.; Hickey, ER.; Lawlor, MD.; Tschantz, MA. Preparation of pyrimidine derivatives useful as inhibitors of PKC-theta for treating various diseases.. 2007. WO2007076247A1
23. Evans DA, Britton TC, Dorow RL, Dellaria JF. Stereoselective amination of chiral enolates. A new approach to the asymmetric synthesis of α -hydrazino and α -amino acid derivatives. *J. Am. Chem. Soc*. 1986; 108:6395–6397.
24. Evans DA, Ennis MD, Mathre DJ. Asymmetric alkylation reactions of chiral imide enolates. A practical approach to the enantioselective synthesis of α -substituted carboxylic acid derivatives. *J. Am. Chem. Soc*. 1982; 104:1737–1739.
25. Evans DA, Kaldor SW, Jones TK, Clardy J, Stout TJ. Total synthesis of the macrolide antibiotic cytotaricin. *J. Am. Chem. Soc*. 1990; 112:7001–7031.
26. Carlson KE, Choi I, Gee A, Katzenellenbogen BS, Katzenellenbogen JA. Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. *Biochemistry*. 1997; 36:14897–14905. [PubMed: 9398213]
27. Katzenellenbogen JA, Johnson HJ Jr, Carlson KE. Studies on the uterine, cytoplasmic estrogen binding protein. Thermal stability and ligand dissociation rate. An assay of empty and filled sites by exchange. *Biochemistry*. 1973; 12:4092–4099. [PubMed: 4745661]
28. Bramlett KS, Wu Y, Burris TP. Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes. *Mol Endocrinol*. 2001; 15:909–922. [PubMed: 11376110]
29. Iannone MA, Simmons CA, Kadwell SH, Svoboda DL, Vanderwall DE, Deng SJ, Consler TG, Shearin J, Gray JG, Pearce KH. Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds. *Mol Endocrinol*. 2004; 18:1064–1081. [PubMed: 14976226]
30. Liu J, Knappenberger KS, Kack H, Andersson G, Nilsson E, Dartsch C, Scott CW. A homogeneous in vitro functional assay for estrogen receptors: coactivator recruitment. *Mol Endocrinol*. 2003; 17:346–355. [PubMed: 12554768]
31. Jeyakumar M, Carlson KE, Gunther JR, Katzenellenbogen JA. Exploration of dimensions of estrogen potency: parsing ligand binding and coactivator binding affinities. *J Biol Chem*. 2011; 286:12971–12982. [PubMed: 21321128]
32. Gunther JR, Du Y, Rhoden E, Lewis I, Revennaugh B, Moore TW, Kim SH, Dingleline R, Fu H, Katzenellenbogen JA. A set of time-resolved fluorescence resonance energy transfer assays for the discovery of inhibitors of estrogen receptor-coactivator binding. *J Biomol Screen*. 2009; 14:181–193. [PubMed: 19196699]
33. Jeyakumar M, Webb P, Baxter JD, Scanlan TS, Katzenellenbogen JA. Quantification of ligand-regulated nuclear receptor corepressor and coactivator binding, key interactions determining

- ligand potency and efficacy for the thyroid hormone receptor. *Biochemistry*. 2008; 47:7465–7476. [PubMed: 18558711]
34. Krey G, Braissant O, L'Horsset F, Kalkhoven E, Perroud M, Parker MG, Wahli W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. *Mol Endocrinol*. 1997; 11:779–791. [PubMed: 9171241]
35. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? *Endocr Rev*. 1999; 20:358–417. [PubMed: 10368776]
36. Stauffer SR, Coletta CJ, Tedesco R, Nishiguchi G, Carlson K, Sun J, Katzenellenbogen BS, Katzenellenbogen JA. Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor- α -selective agonists. *J Med Chem*. 2000; 43:4934–4947. [PubMed: 11150164]
37. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson JA, Carlquist M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. *EMBO J*. 1999; 18:4608–4618. [PubMed: 10469641]
38. Richardson TI, Dodge JA, Wang Y, Durbin JD, Krishnan V, Norman BH. Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 5: Combined A- and C-ring structure-activity relationship studies. *Bioorg Med Chem Lett*. 2007; 17:5563–5566. [PubMed: 17804226]
39. Saijo K, Collier JG, Li AC, Katzenellenbogen JA, Glass CK. An ADIOL-ER β -CtBP transrepression pathway negatively regulates microglia-mediated inflammation. *Cell*. 2011; 145:584–595. [PubMed: 21565615]
40. Kim SH, Tamrazi A, Carlson KE, Daniels JR, Lee IY, Katzenellenbogen JA. Estrogen receptor microarrays: subtype-selective ligand binding. *Journal of the American Chemical Society*. 2004; 126:4754–4755. [PubMed: 15080660]
41. Zhou HB, Carlson KE, Stossi F, Katzenellenbogen BS, Katzenellenbogen JA. Analogs of methyl-piperidinopyrazole (MPP): antiestrogens with estrogen receptor α selective activity. *Bioorg Med Chem Lett*. 2009; 19:108–110. [PubMed: 19014882]

^a Reagents and conditions: (a) pivaloyl chloride, TEA, PhMe, reflux; (b) NaHMDS, THF, -78 °C; then **7**, THF, -78 °C→rt; (c) H₂O₂, LiOH, THF:H₂O (5:1), rt; (d) (i) ClCO₂CH₂CH(CH₃)₂, TEA, THF, -20 °C; then NH₃ (2.0 M in IPA), -20 °C; (ii) TFAA, pyridine, THF, 0 °C; (iii) BBr₃, DCM, -78 °C→rt.

Scheme 1.
Synthesis of *S*-DPN (**2**)^a

Figure 1. Coactivator Titration Assay to Determine Relative Coactivator Binding Affinity (RCA) Values for *rac*-DPN, *R*-DPN and *S*-DPN

The fluorescent donor SA-Tb-ER α or SA-Tb-ER β LBD was titrated against increasing concentration of fluorescein-labeled SRC3 NRID fragment (fluorescent acceptor) in the presence of saturating concentrations of *rac*-DPN, *R*-DPN, *S*-DPN or 17 β -E $_2$ (25 μ M). The results in **Figures 1A** and **1B** show ligand-specific binding curves of total tr-FRET values vs. log SRC3 concentrations for ER α and ER β , respectively. The control FRET (representing the diffusion enhanced FRET; the lowest curves in **Figures 1A** and **1B**) was subtracted from the total FRET values, and the resulting specific FRET binding curves are shown in **Figures 1C** and **1D**. Each assay was performed in duplicate as three independent experiments, and the data from a representative experiment are shown. The concentrations of SRC3 at half-maximal binding (EC_{50}) with both ERs in the presence of different ligands were determined by GraphPad analysis of specific FRET binding curves (**Figures 1C** and **1D**). The RCA of ER α or ER β bound to *rac*-DPN, *R*-DPN or *S*-DPN for SRC3 was determined as the ratio of EC_{50} with 17 β -E $_2$ / EC_{50} with different DPNs multiplied by 100. The mean $\pm$ SD EC_{50} (from six measurements) and the respective RCA values are reported in **Table 2**.

Figure 2. Ligand Titration Assay to Determine Relative Recruitment Potency (RRP) Values for *rac*-DPN, *R*-DPN and *S*-DPN

In these assays, recruitment of a sub-maximal concentration of Fl-SRC3 (100 nM) was evaluated as a function of increasing ligand concentrations. Control-corrected specific FRET values are given. The assay was performed in duplicate at least three times, and the data was analyzed as in **Figures 1C** and **1D**. The concentration of each ligand at 50% SRC3 recruitment (EC_{50}) was calculated, and the RRP of *rac*-DPN, *R*-DPN and *S*-DPN were determined as the ratio of EC_{50} with 17β -E₂/ EC_{50} with different DPNs multiplied by 100. The mean $\pm$ SD of EC_{50} s and RRP from six measurements are shown in **Table 3**.

Figure 3. Determination of the Relative Cellular Potency (RCP) Values for *rac*-DPN, *R*-DPN and *S*-DPN in HEC1 and U2OS cells

HEC-1 (left panels) or U2OS (right panels) cells were transiently transfected with expression plasmids for ERE-luciferase, human ER α (top panels), or ER β (bottom panels), and the internal control β -gal as described in the experimental procedures. Experiments with U2OS cells also contained an expression plasmid for human SRC3 in addition to the aforementioned plasmids. The β -gal-normalized reporter gene responses measured at different concentrations of 17 β -E₂, *rac*-DPN, *R*-DPN, or *S*-DPN are expressed as percent activity of that observed at the highest concentration of 17 β -E₂ with ER α or ER β . Each assay point represents the mean $\pm$ SD of three experiments performed in duplicate. The EC₅₀ response of 17 β -E₂ with both ER α and ER β was set equal to 100%, and the RCP values of the DPNs for each ER were calculated as the ratio of EC₅₀ with 17 β -E₂/EC₅₀ with different DPNs multiplied by 100, and are provided in **Table 4**. A β/α RCP ratio greater than 1 indicates greater cellular potency of ligands towards ER β than ER α .

Table 1Relative ligand binding affinities (RLAs) of *rac*-DPN, *R*-DPN and *S*-DPN

Ligand	RLA (%)		β/α
	ER α	ER β	RLA
E ₂	[100]	[100]	1
R-DPN (3)	0.098 $\pm$ 0.01	32.6 $\pm$ 1.8	332
S-DPN (2)	0.066 $\pm$ 0.007	9.7 $\pm$ 2.3	147
rac-DPN (1)	0.058 $\pm$ 0.006	17.7 $\pm$ 3.6	305

Values are reported as the mean $\pm$ SD or range of two or more independent determinations. The K_d value for estradiol is 0.20 nM for ER α and 0.50 nM for ER β . K_i values for the DPNs can be calculated by the relationship: K_i = (K_d [for E₂] $\times$ 100)/RLA.

Table 2

EC₅₀ values and Relative Coactivator Binding Affinity (RCA) Values for *rac*-DPN, *R*-DPN and *S*-DPN

Ligand	ER α		ER β	
	EC ₅₀ (nM)	RCA (%)	EC ₅₀ (nM)	RCA (%)
E ₂	0.56 ± 0.06	[100]	0.9 ± 0.06	[100]
<i>rac</i> -DPN	3.4 ± 0.4	16.6 ± 1.9	0.71 ± 0.02	126 ± 3.0
<i>R</i> -DPN	2.9 ± 0.3	19.3 ± 2.0	0.8 ± 0.03	112 ± 6.0
<i>S</i> -DPN	6.2 ± 0.9	9.0 ± 1.3	0.76 ± 0.01	119 ± 2.0

Values are reported as the mean ± SD or range of two or more independent determinations

Table 3
EC₅₀ values and Relative Recruitment Potency (RRP) Values for *rac*-DPN, *R*-DPN and *S*-DPN

Ligand	ER α			ER β		
	EC ₅₀ (nM)	RRP (%)	EC ₅₀ (nM)	RRP (%)	β/α RRP	
E ₂	3.0 $\pm$ 0.35	[100]	1.5 $\pm$ 0.1	[100]		1
<i>rac</i> -DPN	876 $\pm$ 16	0.34 $\pm$ 0.02	16.7 $\pm$ 1.5	8.9 $\pm$ 0.9		26
<i>R</i> -DPN	637 $\pm$ 16	0.47 $\pm$ 0.02	10.7 $\pm$ 1.5	14.1 $\pm$ 2.0		30
<i>S</i> -DPN	1403 $\pm$ 45	0.21 $\pm$ 0.01	32.3 $\pm$ 2.5	4.6 $\pm$ 0.35		22

Values are reported as the mean $\pm$ SD or range of two or more independent determinations

Table 4
EC₅₀ values and Relative Cellular Potency (RCP) Values for *rac*-DPN, *R*-DPN and *S*-DPN

Ligand	HEC-1 cells					U2OS cells				
	ER α EC ₅₀ (nM)	ER α RCP (%)	ER β EC ₅₀ (nM)	ER β RCP (%)	β/α RCP	ER α EC ₅₀ (nM)	ER α RCP (%)	ER β EC ₅₀ (nM)	ER β RCP (%)	β/α RCP
E ₂	0.123	100	0.2	100	1	0.150	100	0.4	100	1
<i>rac</i> -DPN	304	0.040	3.3	6.1	153	208	0.072	3.7	10.8	150
<i>R</i> -DPN	286	0.043	3.2	6.3	147	205	0.073	3.4	11.8	162
<i>S</i> -DPN	317	0.039	3.0	6.7	172	212	0.070	3.8	10.5	150

^aRCP is relative cellular potency value, measured relative to that for 17 β -E₂. Therefore, the RCP value for E₂ is 100. Transfection assays were performed with each dose in triplicates three times with similar results, and the data from a representative experiment is shown.